Cervidil is a drug owned by Ferring Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 14, 2012. Details of Cervidil's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5269321 | Retrievable pessary |
Jul, 2012
(14 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Cervidil is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Cervidil's family patents as well as insights into
ongoing legal events
on those patents.
Cervidil's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cervidil:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening | University Hospital, Tours | NA | RECRUITING
(Jul 1, 2026) | PHASE3 |
| Cook´s Balloon Versus Dinoprostone for Labor Induction of Term Pregnancies With Fetal Growth Restriction | Hospital Universitario 12 de Octubre | NA | COMPLETED
(Jul 1, 2026) | PHASE3 |
Generic Launch
Generic Release Date:
Cervidil's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 14, 2012 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cervidil Generics:
There are no approved generic versions for Cervidil as of now.
About Cervidil
Cervidil is a drug owned by Ferring Pharmaceuticals Inc. It is used for managing pelvic organ prolapse. Cervidil uses Dinoprostone as an active ingredient. Cervidil was launched by Ferring in 1995.
Approval Date:
Cervidil was approved by FDA for market use on 30 March, 1995.
Active Ingredient:
Cervidil uses Dinoprostone as the active ingredient. Check out other Drugs and Companies using Dinoprostone ingredient
Treatment:
Cervidil is used for managing pelvic organ prolapse.
Dosage:
Cervidil is available in insert, extended release form for vaginal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG | INSERT, EXTENDED RELEASE | Prescription | VAGINAL |